Baxter (NYSE:BAX) said today it launched a Phase 3 clinical trial of an investigational drug combining a citrate anticoagulant and renal replacement solution. The trial will explore whether the use of the citrate anticoagulant lengthens the extracorporeal circuit life in acute kidney patients undergoing continuous renal replacement therapy, the company said. ”One potential obstacle in delivering […]
Baxter
Baxter jumps on classic Q2 beat-n-raise
Baxter (NYSE:BAX) posted a classic beat-and-raise 2nd quarter today, handily topping expectations on Wall Street, boosting its outlook for the rest of the year and sending its share price up in early trading. The Chicago-area healthcare giant logged profits of $130 million, or 24¢ per share, on sales of $2.56 billion for the 3 months ended […]
Baxter launches Theranova dialyzer in Europe, Down Under
Baxter (NYSE:BAX) said today it launching its novel Theranova HDx hemodialysis therapy system in Australia, New Zealand, France, Germany, Switzerland and Belgium. The device operates around the company’s new Theranova dialyzer designed to extend the range of molecules that it filters from the blood, claiming it “more closely mimics the natural kidney.” ”Through HDx enabled by […]
Baxter recalls select IV fluid filters
Baxter (NYSE:BAX) is recalling its 50mm 0.2 micron filter used to filter water-based intravenous solutions due to the presence of particulate matter and the potential absence of filter layers. The FDA has labeled the recall as Class 1, indicating “a reasonable probability that use of these products will cause serious adverse health consequences or death,” according to […]
Deaths prompt FDA warning on Baxter’s Vascu-Guard patch
Updated to clarify the recent notice did not relate to a recall initiated in June 2015. The FDA today released a notice warning of issues with Baxter‘s (NYSE:BAX) Vascu-Guard peripheral vascular patch after receiving multiple adverse event reports including 3 patient deaths potentially related to the issue. The Vascu-Guard patch is designed for use in […]
Baxter, Satellite Healthcare ink dialysis deal
Baxter (NYSE:BAX) and Satellite Healthcare said today that they inked a deal to bring Baxter’s dialysis products into Satellite’s 80-site renal care network. Satellite, a non-profit group, is the 6th-largest dialysis and kidney disease treatment provider in the U.S. The 4-year deal will see Satellite deploy Baxter’s Amia automated peritoneal dialysis system and Revaclear dialyzer for high-flux hemodialysis. […]
Sunshine Heart pays $5m for Baxter’s Aquadex
UPDATED August 9, 2016, with 2nd-quarter results. Sunshine Heart (NSDQ:SSH) said today that it agreed to pay about $5 million for the Aquadex fluid filtration device Baxter (NYSE:BAX) acquired when it bought Gambro in 2013. The Aquadex device is designed to filter salt and water in patients with renal failure experiencing fluid overload. The deal calls for Eden Prairie, Minn.-based […]
Baxter touts study indicating cost savings with Revaclear dialyzer
Baxter (NYSE:BAX) today released results from a study of its Revaclear high-flux dialyzer, touting lower use of erythropoiesis-stimulating agent with the filter. Use of the Revaclear dialyzer was associated with 100 to 600 fewer units of ESA used per hemodialysis session when compared against Optiflux 160 or Optiflux 180 dialyzers, Deerfield, Ill.-based Baxter said. ”Maintaining hemoglobin […]
Baxter stays steady, lifts guidance after releasing Q2 earnings
Baxter (NYSE:BAX) saw shares stay steady after releasing 2nd quarter earnings today that slimly topped analyst’s expectations, pushing the company to raise its guidance for the next quarter and coming year. Baxter reported profits of $1.2 billion, or $2.19 per share, on sales of $2.6 billion for the 3 months ended June 30. That amounts to […]
Schellhorn out, Emerson in as Monteris CEO | Personnel Moves July 25, 2016
Schellhorn out, Emerson in as Monteris CEO Monteris Medical said last week it tapped ex-Galil Medical prez & CEO Martin Emerson as its new president and chief executive officer, replacing John Schellhorn who left earlier this year. Emerson spent 8 years as prez & CEO of Galil Medical, which was acquired in June this year […]
Report: Medtech M&A values up sharply in 1st half of 2016
The cumulative value of mergers & acquisitions in the medical device space jumped nearly 50% during the 1st half of 2016, even as the total number of deals fell at a double-digit clip, according to MergerMarket. There were some 394 deals worth a total of $74.5 billion during H1 2016, according to the report, marking […]